Novo Nordisk Pharmatech

Novo Nordisk, Wegovy

Novo Nordisk says its high-dose semaglutide trial shows 20.7% weight loss

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight patients lower their weight by 20.7%.

MarketWatch on MSN · 1h

Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows

Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,

Wall Street Journal · 2h

Novo Nordisk’s Wegovy Achieves Weight-Loss of 20.7% at Higher Dose, Study Says

Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side-effects.

STAT · 1h

High-dose Wegovy leads to substantial weight loss in trial, but falls short of Zepbound

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with Zepbound.

Seeking Alpha on MSN · 2h

Novo Nordisk says higher Wegovy dose caused over 20% weight loss in late-stage trial

Novo Nordisk (NVO) announced Friday that a higher-dose version of its popular obesity therapy, semaglutide, marketed as Wegovy led to 20.7% weight loss over 72 weeks compared to 17.5% weight loss achieved by regular semaglutide in a late-stage trial.

US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

1hon MSN

LVMH Reclaims Title of Europe’s Most Valuable Stock From Novo

It’s taken LVMH nearly a year-and-a-half to regain its spot as Europe’s biggest stock from Novo Nordisk A/S.

Finally An Attractive Entry Point Into Novo Nordisk

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...

New York Post27d

Novo Nordisk shares plummet after weight-loss drug’s disappointing trial results

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Fast Company28d

Novo Nordisk stock price takes a tumble after the Wegovy maker’s next-generation weight-loss drug underwhelms

CagriSema, a drug that Novo Nordisk had hoped would become its next generation weight-loss aid, has failed to meet expectations in late-stage trials, sending shares of the pharmaceutical giant ...

Novo Nordisk: From Peak Performance To Needing A Booster Shot

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...

MarketWatch25d

Novo Nordisk’s 27% drop on Friday was a market overreaction, analysts say

Novo Nordisk’s shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema ...

Yahoo Finance4d

Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Wall Street Journal27d

Novo Nordisk Shares Plunge After New Obesity Shot Disappoints

Illustration: Elizabeth Smelov Novo Nordisk’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out nearly $100 billion of the drugmaker ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results